Laboratorios Farmaceuticos Rovi, S.A.

DB:41L Stock Report

Market Cap: €3.2b

Laboratorios Farmaceuticos Rovi Past Earnings Performance

Past criteria checks 3/6

Laboratorios Farmaceuticos Rovi has been growing earnings at an average annual rate of 26.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 17.6% per year. Laboratorios Farmaceuticos Rovi's return on equity is 29.6%, and it has net margins of 20.6%.

Key information

26.1%

Earnings growth rate

23.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate17.6%
Return on equity29.6%
Net Margin20.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Laboratorios Farmaceuticos Rovi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:41L Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247991651550
30 Jun 247781481530
31 Mar 247791381500
31 Dec 238301701470
30 Sep 238371971430
30 Jun 238181861380
31 Mar 238141941340
31 Dec 228182001300
30 Sep 227611761150
30 Jun 227391831100
31 Mar 227241821080
31 Dec 216491531030
30 Sep 21581113950
30 Jun 2151982940
31 Mar 2145071860
31 Dec 2042061850
30 Sep 2041355930
30 Jun 2039553910
31 Mar 2040046930
31 Dec 1938139920
30 Sep 1935533930
30 Jun 1933427930
31 Mar 1931018910
31 Dec 1830318910
30 Sep 1829116900
30 Jun 182839880
31 Mar 1828418870
31 Dec 1727617850
30 Sep 1727722810
30 Jun 1727524810
31 Mar 1727223800
31 Dec 1626526800
30 Sep 1626025840
30 Jun 1625424840
31 Mar 1624623850
31 Dec 1524620840
30 Sep 152422153-9
30 Jun 1524323780
31 Mar 1524125760
31 Dec 1423824750
30 Sep 1423024771
30 Jun 1422424770
31 Mar 1422124780
31 Dec 1321823760

Quality Earnings: 41L has high quality earnings.

Growing Profit Margin: 41L's current net profit margins (20.6%) are lower than last year (23.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 41L's earnings have grown significantly by 26.1% per year over the past 5 years.

Accelerating Growth: 41L's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 41L had negative earnings growth (-16.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).

Return on Equity

High ROE: 41L's Return on Equity (29.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:41
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Álvaro Arístegui EchevarríaAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Javier Esteban LarioBanco de Sabadell. S.A.